Entera Bio (ENTX) Net Cash Flow Growth (3y) (2024 - 2026)
Entera Bio (ENTX) Net Cash Flow Growth (3y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Entera Bio | 186.78 Mn | 182.64 Mn | - | -22.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.25% |
| Dec 31, 2025 | 5.75% |
| Sep 30, 2025 | 7.78% |
| Jun 30, 2025 | 15.47% |
| Mar 31, 2025 | 64.81% |
| Dec 31, 2024 | 39.22% |
| Sep 30, 2024 | -87.25% |
| Jun 30, 2024 | -26.23% |
| Mar 31, 2024 | -30.75% |